In 2026, we will be attending a range of key events across the globe - and we invite you to meet us in person! Join us to discuss ideas, explore opportunities, and see how we can support you and your team in ocular drug development.
Learn more
Experimentica strengthens its position as a leading global ophthalmic CRO by investing in a new GLP‑compliant facility, enabling comprehensive GLP safety and toxicology studies for innovative ocular therapies.
Learn more
Experimentica Ltd., a trusted partner in preclinical drug development for ocular diseases, is pleased to announce the appointment of Teija Parkkari as Director of Business Development, effective April 13, 2026.
Learn more
Experimentica utilizes a validated mouse model of dry eye disease. Dry eye disease-like pathology is induced using transdermal scopolamine patches in combination with desiccating environmental stress. The induced pathology is characterized using corneal fluorescein staining, tear volume measurements, and histology for lacrimal gland infiltration, goblet cell loss, and corneal abnormalities.
Learn more
Meet us at BIO-Europe Spring - let's discuss your preclinical programs!
Learn more
Join us at Life - the biomedical convention 2026 in Heidelberg! Meet our experts and learn about our ophthalmic preclinical models and ocular tissue analysis.
Learn more
Experimentica Ltd., a global contract research organization (CRO) dedicated to preclinical models of ophthalmic diseases, announces a significant expansion of its Kuopio site in Finland.
Learn more
A brief overview of streptozotocin-induced diabetic retinopathy in rodents, highlighting strain-specific differences, quantitative assessment of retinal vascular leakage, identification of the most consistent and reliable readout, and animal welfare considerations.
Learn more
We’re looking forward to participating at BIO-Europe 2025, taking place in Vienna on November 3–5.
Learn more
Glaucoma is a leading cause of irreversible blindness, highlighting the urgent need for reliable preclinical models that capture both structural and functional disease aspects. Our recently published study by Kernius Mickevičius provides a longitudinal evaluation of the rat magnetic microbead model of ocular hypertension by combining multimodal monitoring tools including spectral-domain optical coherence tomography (SD-OCT), pattern electroretinography (pERG), optomotor testing, and morphological analysis.
Learn more
All our facilities are AAALAC accredited, reflecting our commitment to the highest standards of animal care in research.
Copyright: Experimentica Ltd. 2026
